Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics - **Focus**: Precision neuroscience, specifically through receptor-associated proteins - **Lead Program**: RAP-219, a TARP8 AMPA modulator targeting focal onset seizures and bipolar mania [4][5] Key Points and Arguments Product Development and Milestones - **RAP-219**: Demonstrated a best-in-class profile in focal onset seizures with a robust efficacy and tolerability profile [5][8] - **Phase Two Results**: Showed over 70% reduction in seizures over an eight-week period, with 24% of patients achieving complete seizure freedom [9][11] - **FDA Meeting**: Scheduled for Q4 2025 to discuss end of phase two results and path forward for pivotal studies in 2026 [18][19] - **Bipolar Mania Study**: Ongoing evaluation of RAP-219 with expected data in 2027 [5][6] Market Opportunity - **Focal Onset Seizures**: Approximately 1.8 million patients in the U.S. with 30-40% being treatment-resistant, representing a $10 billion-$15 billion market [11][12] - **Polypharmacy Management**: RAP-219 aims to provide a novel mechanism of action with better tolerability compared to existing treatments [12][13] - **Long-Acting Injectable (LAI)**: Development underway, expected to be transformational for patients, with potential for once-monthly or quarterly dosing [15][33][34] Safety and Efficacy - **Tolerability Profile**: RAP-219 showed no severe adverse events, with most being mild or moderate, even among patients on multiple background anti-seizure medications [9][10] - **Long Half-Life**: RAP-219 has a half-life of over 18 days, which may help prevent breakthrough seizures if doses are missed [13][28] Future Data and Expectations - **Upcoming Data Releases**: Full trial results from phase two and open-label extension study expected in 2026 [6][27] - **Phase Three Design**: Standard design anticipated, focusing on seizure reduction and responder analysis [20][21] - **Bipolar Program Read-Through**: Positive implications for RAP-219's efficacy in treating acute mania due to its mechanism targeting glutamate pathways [37][38] Additional Important Insights - **Market Research**: Indicated that RAP-219 will be utilized by both epileptologists and general neurologists across various treatment lines [14] - **Patient Population**: Phase two study included heavily treated patients, suggesting robust efficacy in difficult-to-treat populations [24] - **Regulatory Strategy**: Ongoing discussions with the FDA to align on NDA submission requirements [19][36] This summary encapsulates the critical aspects of Rapport Therapeutics' conference call, highlighting the company's strategic direction, product development, market potential, and future expectations.

Core Viewpoint - The Ministry of Human Resources and Social Security has launched a pilot program in 39 cities to promote the integration of human resources services with the manufacturing industry, focusing on enhancing employment and resource utilization in key manufacturing sectors [1][2]. Group 1: Pilot Cities Characteristics - The selected pilot cities are major economic hubs with significant manufacturing clusters, developed human resources services, abundant educational resources, and strong regional demonstration effects [2]. - These cities have large-scale manufacturing output and strong employment absorption capabilities, representing fast-growing or key manufacturing development areas within their provinces [2]. Group 2: Focus Areas and Implementation - The pilot program will concentrate on key manufacturing sectors such as intelligent manufacturing, electronic information, new materials, new energy, and biotechnology, exploring innovative paths for industrial upgrading and employment promotion [1][2]. - Each pilot city will identify 1 to 3 specific sub-industries for differentiated exploration, leveraging local industrial foundations and unique advantages [2]. - The program aims to create joint recruitment, cross-enterprise training, and innovation coalitions, while accelerating the application of technologies like artificial intelligence and big data [2]. Group 3: Future Steps and Regulation - The Ministry will guide provincial departments and pilot cities in refining their work plans, documenting progress, innovations, and challenges to develop replicable and scalable experiences [3]. - There will be a focus on prudent regulation of new business models and practices, ensuring the protection of labor rights and the legal interests of employers [3].

Group 1 - The core viewpoint of the articles highlights the strengthening of economic and technological cooperation between Vietnam and South Korea, particularly following the elevation of their relationship to a comprehensive strategic partnership in 2022 [1][2] - The bilateral trade volume reached $57.7 billion in the first eight months of 2025, marking a 7.3% year-on-year increase, with South Korea being Vietnam's third-largest trade partner [1] - South Korea remains the leading investor in Vietnam with approximately $94.2 billion in registered capital across 10,301 effective projects as of September 2025 [1] Group 2 - Both countries agreed to enhance collaboration in sectors such as semiconductors, AI, and renewable energy, and to establish joint R&D plans and technology transfer initiatives [2] - From 2026 to 2030, priority projects will focus on transportation infrastructure, urban development, and high-tech infrastructure, with an emphasis on sharing experiences and information [2] - Vietnam aims to leverage South Korea's expertise in infrastructure and high-tech manufacturing to support its goal of becoming a high-income developed country by 2045 [2]

Core Insights - The Ministry of Human Resources and Social Security has issued a notice designating 39 pilot cities for the integration of human resources services and manufacturing industries, focusing on enhancing employment and resource utilization in key manufacturing sectors [1][2] Group 1: Pilot Cities Characteristics - The selected pilot cities are major economic hubs with significant manufacturing clusters, advanced human resources service foundations, and strong educational talent resources [2] - These cities have large-scale manufacturing output and strong employment absorption capabilities, representing fast-growing or key manufacturing development areas within their provinces [2] Group 2: Focus Areas and Tasks - The pilot cities will concentrate on key manufacturing sectors such as intelligent manufacturing, electronic information, new materials, new energy, and biotechnology [1][2] - Each pilot city will identify 1 to 3 specific sub-industries for differentiated exploration, leveraging local industrial foundations and unique advantages [2] - The initiative aims to create joint recruitment, cross-enterprise training, and innovation coalitions to address human resource needs in manufacturing [2] Group 3: Future Steps - The Ministry will guide provincial human resources departments and pilot cities to refine their work plans, documenting progress, innovations, and challenges to develop replicable and scalable experiences [3] - There will be a focus on prudent regulation of new business models and practices, ensuring the protection of labor rights and the legal interests of employers [3]

Core Viewpoint - The Ministry of Human Resources and Social Security has announced 39 pilot cities for the integration of human resources services and manufacturing industries, aiming to enhance employment and resource utilization in key manufacturing sectors [1][2]. Group 1: Pilot Cities Characteristics - The selected pilot cities are major economic hubs with significant manufacturing clusters, developed human resources services, abundant educational resources, and strong regional influence [2]. - These cities have large manufacturing output and strong employment absorption capabilities, representing fast-growing or significant manufacturing development areas within their provinces [2]. Group 2: Focus Areas and Tasks - The pilot cities will concentrate on key manufacturing sectors such as intelligent manufacturing, electronic information, new materials, new energy, and biotechnology [1][2]. - Each pilot city will identify 1 to 3 specific sub-industries for differentiated exploration, leveraging local industrial foundations and unique advantages [2]. - The initiative aims to create joint recruitment, cross-enterprise training, and innovation coalitions to address human resource needs in manufacturing [2]. Group 3: Future Steps - The Ministry will guide provincial departments and pilot cities in refining their work plans, documenting progress, innovations, and challenges to develop replicable and scalable experiences [3]. - There will be a focus on prudent regulation of new business models and practices, while ensuring the protection of labor rights and combating illegal activities such as false recruitment and discrimination [3].

Financial Data and Key Metrics Changes - The company ended Q3 2025 with a cash balance of $14.3 million and raised an additional $1.2 million since the quarter end, providing a runway through 2026 [23] - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024 [23] - For the nine months ended September 30, 2025, the net loss was $9.9 million, or $2.39 per share, compared to $8.3 million, or $2.24 per share for the same period in 2024 [23] Business Line Data and Key Metrics Changes - The ongoing trial of agenT-797, an allo off-the-shelf iNKT cell therapy, showed a median overall survival of approximately 23 months in patients with relapsed or refractory solid tumors when combined with PD-1 therapies [4] - Observations included complete remission in a patient with metastatic testicular cancer and durable partial responses in other difficult-to-treat cancers, demonstrating the potential of agenT-797 to restore immune function [5][6] Market Data and Key Metrics Changes - The company has established a strategic partnership with the University of Wisconsin Carbone Cancer Center to advance the iNKT program in immune reconstitution following stem cell transplantation [10] - The company is preparing for a global phase II trial in acute pulmonary dysfunction with multi-drug resistant infections, targeting a patient demographic that mirrors U.S. demographics [12] Company Strategy and Development Direction - MiNK Therapeutics is focused on advancing its iNKT Cell Therapy platform and has become the most clinically advanced company in developing allogeneic iNKT cells [8] - The company aims to redefine immune recovery in various conditions, including cancer, infection, critical illness, and transplantation, through innovative partnerships and disciplined capital use [9][22] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of building public-private partnerships and emphasized the potential of iNKT cells to transform treatment in critical illness and transplantation [9][22] - The company expects to have multiple clinical programs actively enrolling patients by this time next year, with early readouts emerging from GVHD and pulmonary cohorts [28] Other Important Information - The company executed an at-the-market sales agreement, leveraging a significant increase in equity price to access cash while limiting dilution to shareholders [26] - The leadership team has been strengthened with the onboarding of Dr. John Holcomb and Dr. Therese Hammond, enhancing the company's clinical and operational capabilities [25] Q&A Session Summary Question: Expansion of the combination therapy cohort - Management indicated plans to expand the cohort for the combination therapy with PD-1, with a focus on patients who have failed prior PD-1 therapy, and will announce an expanded cohort moving into a phase two study [33][34] Question: Timing for the severe pulmonary disease trial - The company is in the activation phase and aims to dose the first patient by early next year, with efforts to initiate patient enrollment imminently [38] Question: Details on GVHD and pulmonary inflammation trials - Management provided insights into the GVHD trial, emphasizing endpoints such as GVHD presence or absence and the potential for significant improvements in patient outcomes [44][46] - For the pulmonary disease trial, the primary endpoint will be 28-day mortality, with a focus on patients with severe pneumonia and hypoxemic respiratory failure [51]

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Yingpai Pharmaceutical, which is required to clarify the pricing basis for past capital increases and share transfers, and whether there have been any instances of shareholding representation since its establishment [1] - Yingpai Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 26, with Goldman Sachs and CICC as joint sponsors [1] - The CSRC has requested legal opinions on the compliance of the company's past equity changes, including whether there are any unfulfilled capital contributions or irregularities in the contribution methods [1][2] Group 2 - Yingpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced synthetic lethality product portfolio and is one of only three companies globally with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - The core product, Senaparib, is a PARP1/2 inhibitor approved in China for first-line maintenance treatment of ovarian cancer in January 2025, showing the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically addressing Nanjing Inpai Pharmaceutical Co., Ltd. and its compliance with various regulatory aspects [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Inpai Pharmaceutical to clarify the pricing basis for its past capital increases and equity transfers, and to confirm whether there have been any violations regarding capital contributions or shareholding legality [1] - The company is also required to provide details on the compliance of its three overseas subsidiaries with foreign investment and foreign exchange registration regulations [1] - Additionally, the CSRC seeks confirmation on whether there have been any instances of shareholding representation since the company's establishment [1] Group 2: Shareholder Compliance - The company must disclose whether any shareholders holding more than 5% of shares have any domestic entities that are prohibited from holding shares under relevant laws and regulations [1] Group 3: Business Operations and Compliance - Inpai Pharmaceutical is required to explain its business scope and operations in relation to human stem cells, gene diagnosis, and treatment technologies, ensuring compliance with foreign investment policies [2] - The company must also confirm that its proposed issuance plan aligns with the regulatory guidelines for overseas listings and clarify the status of shares held by shareholders participating in the "full circulation" [2] Group 4: Company Overview - Inpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced portfolio of synthetic lethality products and is one of only three companies globally with both commercialized PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - Its core product, Senaparib, is a PARP1/2 inhibitor approved in January 2025 for first-line maintenance treatment of ovarian cancer in China, demonstrating the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Group 1: Funding Highlights in the Medical Sector - LambdaVision completed a $7 million angel round financing, with investments from Aurelia Foundry, Seraphim Space, and Seven Seven Six. The company is based in the USA and focuses on developing artificial retinas [1] - CustoMED secured $6 million in seed funding, with participation from Emerging Longevity Ventures, FLAG Capital Management, Longevity Venture Partners, Varana Capital, and the Israeli Innovation Authority. CustoMED is located in Israel and specializes in personalized and precision surgical technologies [1] - Microbio completed an angel round financing exceeding 100 million RMB, led by Qiming Venture Partners. The company is based in Shanghai and is an innovator in the in vivo cell therapy field, focusing on CAR-T therapies for hematological malignancies and autoimmune diseases [1] Group 2: Notable Financing Events - Zijing Zhikang raised nearly 100 million RMB in angel round financing, led by Xinglian Capital, with participation from Inno Angel Fund and Shangshi Capital. The company is located in Wuxi and develops medical intelligent algorithms [2] - Zhiyuan Shilan completed tens of millions in angel round financing, led by Woyan Capital, with continued support from existing investors. The company is based in Beijing and focuses on data-driven biomolecular design and manufacturing [2] - Azalea Tx raised a total of $82 million in seed and Series A financing, with participation from RA Capital Management, Sozo Ventures, Third Rock Ventures, and Yosemite. The company is based in the USA and specializes in precision genome editing technologies [2] Group 3: Advanced Medical Technologies - Curve Biosciences completed a $40 million Series A financing led by Luma Group. The company is based in the USA and offers a comprehensive smart platform for chronic disease monitoring [3] - Xiyuan Anjian raised over 200 million RMB in Series A financing, with investments from multiple venture capital firms. The company is located in Beijing and focuses on developing innovative biopharmaceuticals for tumors and chronic diseases [3] - AAVantgarde Bio secured $141 million in Series B financing, with participation from several prominent investment firms. The company is based in Italy and specializes in treatments for hereditary eye diseases [3] Group 4: Robotics and Innovative Drug Development - Agile Medical completed several hundred million RMB in Series B financing, led by Mingxi Capital. The company is based in Suzhou and specializes in surgical robotics [4] - Sovato raised Series B financing from multiple well-known investment institutions. The company is based in the USA and focuses on global remote robotic surgery services [4] - Yangli Pharmaceutical completed a significant Series B financing, exclusively led by Qiming Venture Partners. The company is located in Hangzhou and is engaged in innovative drug development [4] Group 5: Strategic Investments in Medical Innovations - Quanzhen Medical completed 100 million RMB in Series B financing, including a strategic round from an A-share listed company and additional funding from Good Doctor Group. The company is based in Hangzhou and focuses on medical large model innovations [5] - Andao Pharmaceutical raised over 400 million RMB in Series C financing, with investments from various funds and institutions. The company is located in Hangzhou and specializes in new drug development for kidney diseases, anemia, and cancer [5]

Core Viewpoint - The Hong Kong stock market has seen significant gains in certain biotechnology stocks, with notable increases in share prices for several companies on November 14. Group 1: Stock Performance - The newly listed company 旺山旺水 has surged over 25%, leading the gains in the biotechnology sector [1] - 圣诺医药 has experienced an increase of over 17% [1] - 基石药业 has risen nearly 17% [1] - 劲方医药 has seen an increase of over 8% [1]